Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Among early phase trials, exenatide studies showed the highest mean eligibility rates (60.6%, 62.5%, and 64.4% for Non-Asian US, Asian US, and Korean, respectively), followed by liraglutide (54.0%, 47.5%, 40.3%)
Effectiveness for Weight Management Studies have shown that semaglutide can lead to significant weight loss
For example, in Liraglutide trials, 3.1% of participants developed gallbladder disease compared to 1.9% in the placebo group
Insurance companies have been known to discontinue coverage if diabetic targets are reached (HgbA1C, Fasting glucose)
US$ 29.03
US$ 26.98
US$ 23.91
US$ 26.56
